Potential New Therapeutic Approaches for Renal Cell Carcinoma

David C. Yang, Ching Hsien Chen

Research output: Contribution to journalReview articlepeer-review

Abstract

Summary: Renal cell carcinoma (RCC) is increasing in incidence and one third of newly diagnosed cases already are metastatic. The metastatic spread of solid tumors renders RCC incurable by surgical resection and consequently more difficult to treat. New molecular-targeted therapies have played a pivotal role in RCC treatment. Unfortunately, tumors frequently develop resistance to these targeted therapies by activating bypass pathways in which alternative signaling or biochemical pathways are activated in response to targeted inhibition of a signaling pathway, allowing cancer cells to continue to survive. Although the advent of immunotherapy with checkpoint inhibitors has led to significant changes in the treatment landscape for advanced RCC, many issues remain to be resolved. For these reasons, there is an urgent need to develop novel therapies and new treatment paradigms for patients with RCC. Much research has been performed thus far in identifying novel targets and treatment strategies in RCC and many of these currently are under investigation and/or in clinical trials. In this article, we discuss therapeutic options in the management of RCC with a focus on the new therapeutic approaches currently investigated in research and for use in the clinic. We divide these potential novel therapies into five groups: nonbiologics, small-molecule drugs, biologics, immunomodulatory therapies, and peptide drugs. We also present some therapeutics and treatment paradigms.

Original languageEnglish (US)
Pages (from-to)86-97
Number of pages12
JournalSeminars in Nephrology
Volume40
Issue number1
DOIs
StatePublished - Jan 2020

Keywords

  • biologics
  • Biotherapeutics
  • immunomodulatory drugs
  • kidney cancer
  • small molecules

ASJC Scopus subject areas

  • Nephrology

Fingerprint Dive into the research topics of 'Potential New Therapeutic Approaches for Renal Cell Carcinoma'. Together they form a unique fingerprint.

Cite this